4th Quarter - Report

TIBER CREEK GROUP for ASTELLAS PHARMA US, INC.

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

issues relating to drug pricing, march-in rights under Bayh-Dole Act P.L. 96-517 and transparency. S.1519, the National Defense Authorization Act for 2018, Section 892, Rights in technical data related to medical research. HR 2819 - National Defense Authorization Act (FY18), Amendment 342, Rep. Doggett

Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

LobbyistCovered position, as disclosed
JOHN MICHAEL GONZALEZ —
JONATHON JONES —
SEAN RICHARDSON —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2819 (115th), S. 1519 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.